6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
(	(	(	(	(	N	O
incidence	JJ	incidence	incidence	incid	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
chromaturia	NN	chromaturia	chromaturia	chromaturia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
and	CC	and	and	and	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O

SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
ApoPharma	NNP	apopharma	apopharma	apopharma	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
:	:	:	:	:	N	O
Telephone	NN	telephone	telephone	telephon	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
866	CD	866	866	866	N	O
-	:	-	-	-	N	O
949	CD	949	949	949	N	O
-	:	-	-	-	N	O
0995	CD	0995	0995	0995	N	O

Email	NN	email	email	email	N	O
:	:	:	:	:	N	O
medicalsafety	NN	medicalsafety	medicalsafety	medicalsafeti	N	O
apopharma	NN	apopharma	apopharma	apopharma	N	O
.	.	.	.	.	N	O
com	NN	com	com	com	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
also	RB	also	also	also	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O
Agranulocytosis	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
plasma	NN	plasma	plasma	plasma	N	I-AdverseReaction
zinc	NN	zinc	zinc	zinc	Y	I-AdverseReaction
concentrations	NNS	concentrations	concentration	concentr	N	I-AdverseReaction
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
represents	VBZ	represents	represents	repres	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
data	NNS	data	data	data	N	O
collected	VBN	collected	collected	collect	N	O
from	IN	from	from	from	N	O
642	CD	642	642	642	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
participated	VBD	participated	participated	particip	N	O
in	IN	in	in	in	N	O
single	JJ	single	single	singl	N	O
arm	NN	arm	arm	arm	N	O
or	CC	or	or	or	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
was	VBD	was	wa	wa	N	O
agranulocytosis	JJ	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
during	IN	during	during	dure	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
chromaturia	NNS	chromaturia	chromaturia	chromaturia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
table	NN	table	table	tabl	N	O
below	IN	below	below	below	N	O
lists	VBZ	lists	list	list	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
642	CD	642	642	642	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O

Body	NN	body	body	bodi	N	O
System	NNP	system	system	system	N	O
Subjects	NNP	subjects	subject	subject	N	O

Preferred	JJ	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O

BLOOD	NNP	blood	blood	blood	N	O
AND	NNP	and	and	and	N	O
LYMPHATIC	NNP	lymphatic	lymphatic	lymphat	N	O
SYSTEM	NNP	system	system	system	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
6.2	CD	6.2	6.2	6.2	N	O

Agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
1.7	CD	1.7	1.7	1.7	N	O

GASTROINTESTINAL	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
12.6	CD	12.6	12.6	12.6	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
discomfort	NN	discomfort	discomfort	discomfort	Y	I-AdverseReaction
10.4	CD	10.4	10.4	10.4	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
9.8	CD	9.8	9.8	9.8	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
3.0	CD	3.0	3.0	3.0	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
2.0	CD	2.0	2.0	2.0	N	O

INVESTIGATIONS	NN	investigations	investigation	investig	N	O

Alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
Aminotransferase	NNP	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
7.5	CD	7.5	7.5	7.5	N	O

Neutrophil	NNP	neutrophil	neutrophil	neutrophil	N	B-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
7.3	CD	7.3	7.3	7.3	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
1.9	CD	1.9	1.9	1.9	N	O

Aspartate	NNP	aspartate	aspartate	aspart	N	B-AdverseReaction
Aminotransferase	NNP	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
1.2	CD	1.2	1.2	1.2	N	O

METABOLISM	NNP	metabolism	metabolism	metabol	N	O
AND	CC	and	and	and	N	O
NUTRITION	NNP	nutrition	nutrition	nutrit	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
4.0	CD	4.0	4.0	4.0	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
1.1	CD	1.1	1.1	1.1	N	O

MUSCULOSKELETAL	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
AND	NNP	and	and	and	N	O
CONNECTIVE	NNP	connective	connective	connect	N	O
TISSUE	NNP	tissue	tissue	tissu	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Arthralgia	$	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
9.8	CD	9.8	9.8	9.8	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
2.0	CD	2.0	2.0	2.0	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
1.9	CD	1.9	1.9	1.9	N	O

Arthropathy	$	arthropathy	arthropathy	arthropathi	Y	B-AdverseReaction
1.4	CD	1.4	1.4	1.4	N	O

NERVOUS	NNP	nervous	nervous	nervou	Y	O
SYSTEM	NNP	system	system	system	N	O
DISORDERS	NNP	disorders	disorder	disord	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
2.5	CD	2.5	2.5	2.5	N	O

URINARY	NN	urinary	urinary	urinari	N	O
DISORDERS	NNS	disorders	disorder	disord	N	O

Chromaturia	NNS	chromaturia	chromaturia	chromaturia	Y	B-AdverseReaction
14.6	CD	14.6	14.6	14.6	N	O

Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
by	IN	by	by	by	N	O
patients	NNS	patients	patient	patient	N	O
participating	VBG	participating	participating	particip	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Chromaturia	NNS	chromaturia	chromaturia	chromaturia	Y	B-AdverseReaction

(	(	(	(	(	N	O
reddish	JJ	reddish	reddish	reddish	N	O
brown	VBN	brown	brown	brown	N	O
discoloration	NN	discoloration	discoloration	discolor	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
urine	NN	urine	urine	urin	N	O
)	)	)	)	)	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
result	NN	result	result	result	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
excretion	NN	excretion	excretion	excret	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
iron	NN	iron	iron	iron	Y	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
urine	NN	urine	urine	urin	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
additional	JJ	additional	additional	addit	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
thrombocytosis	NN	thrombocytosis	thrombocytosis	thrombocytosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

Congenital	NNP	congenital	congenital	congenit	N	O
,	,	,	,	,	N	O
familial	JJ	familial	familial	famili	N	O
and	CC	and	and	and	N	O
genetic	JJ	genetic	genetic	genet	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hypospadias	NN	hypospadias	hypospadias	hypospadia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Eye	JJ	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
diplopia	NN	diplopia	diplopia	diplopia	Y	B-AdverseReaction
,	,	,	,	,	N	O
papilledema	NN	papilledema	papilledema	papilledema	Y	B-AdverseReaction
,	,	,	,	,	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
,	,	,	,	,	N	O
rectal	JJ	rectal	rectal	rectal	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastric	JJ	gastric	gastric	gastric	N	B-AdverseReaction
ulcer	NN	ulcer	ulcer	ulcer	Y	I-AdverseReaction
,	,	,	,	,	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
,	,	,	,	,	N	O
parotid	JJ	parotid	parotid	parotid	N	B-AdverseReaction
gland	NN	gland	gland	gland	N	I-AdverseReaction
enlargement	NN	enlargement	enlargement	enlarg	N	I-AdverseReaction
.	.	.	.	.	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
edema	JJ	edema	edema	edema	Y	B-AdverseReaction
peripheral	NN	peripheral	peripheral	peripher	N	I-AdverseReaction
,	,	,	,	,	N	O
multi	SYM	multi	multi	multi	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
organ	JJ	organ	organ	organ	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	B-AdverseReaction
,	,	,	,	,	N	O
hepatomegaly	NN	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
.	.	.	.	.	N	O

Immune	NNP	immune	immune	immun	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
.	.	.	.	.	N	O

I	PRP	i	i	i	N	O
nfections	NNS	nfections	nfections	nfection	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
cryptococcal	JJ	cryptococcal	cryptococcal	cryptococc	N	B-AdverseReaction
cutaneous	JJ	cutaneous	cutaneous	cutan	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
enteroviral	JJ	enteroviral	enteroviral	enterovir	N	B-AdverseReaction
encephalitis	NN	encephalitis	encephalitis	enceph	Y	I-AdverseReaction
,	,	,	,	,	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
furuncle	NN	furuncle	furuncle	furuncl	Y	B-AdverseReaction
,	,	,	,	,	N	O
infectious	JJ	infectious	infectious	infecti	N	B-AdverseReaction
hepatitis	NN	hepatitis	hepatitis	hepat	Y	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
pustular	NN	pustular	pustular	pustular	N	I-AdverseReaction
,	,	,	,	,	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	B-AdverseReaction
abscess	NN	abscess	abscess	abscess	Y	I-AdverseReaction
.	.	.	.	.	N	O

Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
creatinine	JJ	creatinine	creatinine	creatinin	Y	I-AdverseReaction
phosphokinase	NN	phosphokinase	phosphokinase	phosphokinas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
.	.	.	.	.	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
metabolic	JJ	metabolic	metabolic	metabol	N	B-AdverseReaction
acidosis	NN	acidosis	acidosis	acidosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
.	.	.	.	.	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
myositis	NN	myositis	myositis	myositi	Y	B-AdverseReaction
,	,	,	,	,	N	O
chondropathy	NN	chondropathy	chondropathy	chondropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
trismus	NN	trismus	trismus	trismu	Y	B-AdverseReaction
.	.	.	.	.	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
cerebellar	JJ	cerebellar	cerebellar	cerebellar	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
convulsion	NN	convulsion	convulsion	convuls	Y	B-AdverseReaction
,	,	,	,	,	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction
,	,	,	,	,	N	O
intracranial	JJ	intracranial	intracranial	intracrani	N	B-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
psychomotor	NN	psychomotor	psychomotor	psychomotor	N	B-AdverseReaction
skills	NNS	skills	skill	skill	N	I-AdverseReaction
impaired	VBD	impaired	impaired	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
pyramidal	JJ	pyramidal	pyramidal	pyramid	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
.	.	.	.	.	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
bruxism	NN	bruxism	bruxism	bruxism	Y	B-AdverseReaction
,	,	,	,	,	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction
,	,	,	,	,	N	O
obsessive	JJ	obsessive	obsessive	obsess	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
compulsive	JJ	compulsive	compulsive	compuls	N	I-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
glycosuria	NN	glycosuria	glycosuria	glycosuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
hemoglobinuria	NN	hemoglobinuria	hemoglobinuria	hemoglobinuria	Y	B-AdverseReaction
.	.	.	.	.	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
acute	NN	acute	acute	acut	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
distress	NN	distress	distress	distress	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
epistaxis	NN	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
hemoptysis	NN	hemoptysis	hemoptysis	hemoptysi	Y	B-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	O
,	,	,	,	,	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
,	,	,	,	,	N	O
periorbital	JJ	periorbital	periorbital	periorbit	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
photosensitivity	NN	photosensitivity	photosensitivity	photosensit	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
pruritis	NN	pruritis	pruritis	pruriti	N	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
Henoch	NNP	henoch	henoch	henoch	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Schonlein	NNP	schonlein	schonlein	schonlein	N	I-AdverseReaction
purpura	NN	purpura	purpura	purpura	Y	I-AdverseReaction
.	.	.	.	.	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
AGRANULOCYTOSIS	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
NEUTROPENIA	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
AGRANULOCYTOSIS	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
NEUTROPENIA	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
that	WDT	that	that	that	N	O
can	MD	can	can	can	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
precede	VB	precede	precede	preced	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
\n	JJ	\n	\n	\n	N	O
Measure	NNP	measure	measure	measur	N	O
the	DT	the	the	the	N	O
absolute	NN	absolute	absolute	absolut	N	O
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
)	)	)	)	)	N	O
before	IN	before	before	befor	N	O
starting	VBG	starting	starting	start	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
the	DT	the	the	the	N	O
ANC	NNP	anc	anc	anc	N	O
weekly	NN	weekly	weekly	weekli	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
therapy	NN	therapy	therapy	therapi	N	O
if	IN	if	if	if	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	O
develops	NNS	develops	develops	develop	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NNP	)]	)]	)]	N	O
\n	NNP	\n	\n	\n	N	O
Interrupt	NNP	interrupt	interrupt	interrupt	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
if	IN	if	if	if	N	O
infection	NN	infection	infection	infect	Y	O
develops	VBZ	develops	develops	develop	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
the	DT	the	the	the	N	O
ANC	NNP	anc	anc	anc	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
\n	NNP	\n	\n	\n	N	O
Advise	NNP	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
to	TO	to	to	to	N	O
report	VB	report	report	report	N	O
immediately	RB	immediately	immediately	immedi	N	O
any	DT	any	any	ani	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
indicative	NN	indicative	indicative	indic	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NNP	)]	)]	)]	N	O
\n	NNP	\n	\n	\n	N	O
\n	NNP	\n	\n	\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
EXCERPT	NNP	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
AGRANULOCYTOSIS	NNP	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
NEUTROPENIA	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
that	WDT	that	that	that	N	O
can	MD	can	can	can	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
infections	NNS	infections	infection	infect	N	B-AdverseReaction
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
precede	VB	precede	precede	preced	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
Measure	NN	measure	measure	measur	N	O
the	DT	the	the	the	N	O
absolute	NN	absolute	absolute	absolut	N	O
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
)	)	)	)	)	N	O
before	IN	before	before	befor	N	O
starting	VBG	starting	starting	start	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
the	DT	the	the	the	N	O
ANC	NNP	anc	anc	anc	N	O
weekly	NN	weekly	weekly	weekli	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
Interrupt	NNP	interrupt	interrupt	interrupt	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
if	IN	if	if	if	N	O
infection	NN	infection	infection	infect	Y	O
develops	NNS	develops	develops	develop	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
the	DT	the	the	the	N	O
ANC	NNP	anc	anc	anc	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
Advise	NNP	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
to	TO	to	to	to	N	O
report	VB	report	report	report	N	O
immediately	RB	immediately	immediately	immedi	N	O
any	DT	any	any	ani	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
indicative	NN	indicative	indicative	indic	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
If	IN	if	if	if	N	O
infection	NN	infection	infection	infect	Y	O
occurs	VBZ	occurs	occurs	occur	N	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
,	,	,	,	,	N	O
interrupt	JJ	interrupt	interrupt	interrupt	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
the	DT	the	the	the	N	O
ANC	NNP	anc	anc	anc	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
while	IN	while	while	while	N	O
on	IN	on	on	on	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	O

Neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
with	IN	with	with	with	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
can	MD	can	can	can	N	B-Factor
also	RB	also	also	also	N	O
cause	VB	cause	cause	caus	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
foreshadow	VB	foreshadow	foreshadow	foreshadow	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
.	.	.	.	.	N	O

Measure	NN	measure	measure	measur	N	O
the	DT	the	the	the	N	O
absolute	NN	absolute	absolute	absolut	N	O
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
)	)	)	)	)	N	O
before	IN	before	before	befor	N	O
starting	VBG	starting	starting	start	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
the	DT	the	the	the	N	O
ANC	NNP	anc	anc	anc	N	O
weekly	NN	weekly	weekly	weekli	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
therapy	NN	therapy	therapy	therapi	N	O
if	IN	if	if	if	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	O
develops	NNS	develops	develops	develop	N	O
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
1.5	CD	1.5	1.5	1.5	N	O
x	VBD	x	x	x	N	O
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O
L	NNP	l	l	l	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
if	IN	if	if	if	N	O
infection	NN	infection	infection	infect	Y	O
develops	VBZ	develops	develops	develop	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
the	DT	the	the	the	N	O
ANC	NNP	anc	anc	anc	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
to	TO	to	to	to	N	O
immediately	RB	immediately	immediately	immedi	N	O
interrupt	VB	interrupt	interrupt	interrupt	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
report	NN	report	report	report	N	O
to	TO	to	to	to	N	O
their	PRP$	their	their	their	N	O
physician	JJ	physician	physician	physician	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
experience	VBP	experience	experience	experi	N	O
any	DT	any	any	ani	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
indicative	NN	indicative	indicative	indic	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
pooled	JJ	pooled	pooled	pool	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
is	VBZ	is	is	is	N	O
unknown	JJ	unknown	unknown	unknown	N	O
.	.	.	.	.	N	O

Agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
usually	RB	usually	usually	usual	N	O
resolve	VBP	resolve	resolve	resolv	N	O
upon	IN	upon	upon	upon	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
there	RB	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	B-AdverseReaction
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Implement	VB	implement	implement	implement	N	O
a	DT	a	a	a	N	O
plan	NN	plan	plan	plan	N	O
to	TO	to	to	to	N	O
monitor	VB	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
manage	VB	manage	manage	manag	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
1.5	CD	1.5	1.5	1.5	N	O
x	VBD	x	x	x	N	O
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O
L	NNP	l	l	l	N	O
and	CC	and	and	and	N	O
0.5	CD	0.5	0.5	0.5	N	O
x	NNS	x	x	x	N	O
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O
L	NNP	l	l	l	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O

Instruct	IN	instruct	instruct	instruct	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
to	TO	to	to	to	N	O
immediately	RB	immediately	immediately	immedi	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
other	JJ	other	other	other	N	O
medications	NNS	medications	medication	medic	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
potential	JJ	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
.	.	.	.	.	N	O

Obtain	VB	obtain	obtain	obtain	N	O
a	DT	a	a	a	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
(	(	(	(	(	N	O
CBC	NNP	cbc	cbc	cbc	Y	O
)	)	)	)	)	N	O
count	NN	count	count	count	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
a	DT	a	a	a	N	O
white	JJ	white	white	white	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
(	(	(	(	(	N	O
WBC	NNP	wbc	wbc	wbc	Y	O
)	)	)	)	)	N	O
count	NN	count	count	count	N	O
corrected	VBN	corrected	corrected	correct	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
presence	NN	presence	presence	presenc	N	O
of	IN	of	of	of	N	O
nucleated	JJ	nucleated	nucleated	nucleat	N	O
red	JJ	red	red	red	N	O
blood	NN	blood	blood	blood	N	O
cells	NNS	cells	cell	cell	N	O
,	,	,	,	,	N	O
an	DT	an	an	an	N	O
absolute	JJ	absolute	absolute	absolut	N	O
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	O
count	NN	count	count	count	N	O
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
platelet	NN	platelet	platelet	platelet	N	O
count	NN	count	count	count	N	O
daily	RB	daily	daily	daili	N	O
until	IN	until	until	until	N	O
recovery	NN	recovery	recovery	recoveri	N	O
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
1.5	CD	1.5	1.5	1.5	N	O
x	VBD	x	x	x	N	O
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O
L	NNP	l	l	l	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	O
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
0.5	CD	0.5	0.5	0.5	N	O
x	VBD	x	x	x	N	O
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O
L	NNP	l	l	l	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O

Consider	VB	consider	consider	consid	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
management	NN	management	management	manag	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
resume	VB	resume	resume	resum	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
developed	VBN	developed	developed	develop	N	O
agranulocytosis	NN	agranulocytosis	agranulocytosis	agranulocytosi	Y	O
unless	IN	unless	unless	unless	N	O
potential	JJ	potential	potential	potenti	N	O
benefits	NNS	benefits	benefit	benefit	N	O
outweigh	VBP	outweigh	outweigh	outweigh	N	O
potential	JJ	potential	potential	potenti	N	O
risks	NNS	risks	risk	risk	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
rechallenge	VB	rechallenge	rechallenge	rechalleng	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
with	IN	with	with	with	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
unless	IN	unless	unless	unless	N	O
potential	JJ	potential	potential	potenti	N	O
benefits	NNS	benefits	benefit	benefit	N	O
outweigh	VBP	outweigh	outweigh	outweigh	N	O
potential	JJ	potential	potential	potenti	N	O
risks	NNS	risks	risk	risk	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
genotoxicity	NN	genotoxicity	genotoxicity	genotox	N	B-AdverseReaction
and	CC	and	and	and	N	O
developmental	JJ	developmental	developmental	development	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
in	IN	in	in	in	N	O
animal	JJ	animal	animal	anim	N	B-Animal
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
animal	JJ	animal	animal	anim	N	B-Animal
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
deferiprone	NN	deferiprone	deferiprone	deferipron	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
period	NN	period	period	period	N	O
of	IN	of	of	of	N	O
organogenesis	NN	organogenesis	organogenesis	organogenesi	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
embryofetal	JJ	embryofetal	embryofetal	embryofet	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
and	CC	and	and	and	N	O
malformations	NNS	malformations	malformation	malform	N	I-AdverseReaction
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
equivalent	JJ	equivalent	equivalent	equival	N	O
human	JJ	human	human	human	N	O
clinical	JJ	clinical	clinical	clinic	N	O
doses	NNS	doses	dos	dose	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
when	WRB	when	when	when	N	O
taking	VBG	taking	taking	take	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Nonclinical	NNP	nonclinical	nonclinical	nonclin	N	O
Toxicology	NNP	toxicology	toxicology	toxicolog	N	O
(	(	(	(	(	N	O
13.1	CD	13.1	13.1	13.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Laboratory	NN	laboratory	laboratory	laboratori	N	O
Tests	NNS	tests	test	test	N	O

Serum	NNP	serum	serum	serum	N	O
Liver	NNP	liver	liver	liver	N	O
Enzyme	NNP	enzyme	enzyme	enzym	N	O
Activities	NNP	activities	activity	activ	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
7.5%	CD	7.5%	7.5%	7.5%	N	O
of	IN	of	of	of	N	O
642	CD	642	642	642	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
developed	VBD	developed	developed	develop	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
values	NNS	values	value	valu	N	I-AdverseReaction
.	.	.	.	.	N	O

Four	CD	four	four	four	N	O
(	(	(	(	(	N	O
0.62%	CD	0.62%	0.62%	0.62%	N	O
)	)	)	)	)	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
subjects	NNS	subjects	subject	subject	N	O
discontinued	VBD	discontinued	discontinued	discontinu	N	O
the	DT	the	the	the	N	O
drug	NN	drug	drug	drug	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
levels	NNS	levels	level	level	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.16%	CD	0.16%	0.16%	0.16%	N	O
)	)	)	)	)	N	O
due	NN	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
both	DT	both	both	both	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
serum	NN	serum	serum	serum	N	O
ALT	NNP	alt	alt	alt	N	O
values	VBZ	values	value	valu	N	O
monthly	JJ	monthly	monthly	monthli	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
consider	VB	consider	consider	consid	N	O
interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
if	IN	if	if	if	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
persistent	JJ	persistent	persistent	persist	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
serum	JJ	serum	serum	serum	N	O
transaminase	NN	transaminase	transaminase	transaminas	N	O
levels	NNS	levels	level	level	N	O
.	.	.	.	.	N	O

Plasma	NNP	plasma	plasma	plasma	N	O
Zinc	NNP	zinc	zinc	zinc	Y	O
Concentration	NNP	concentration	concentration	concentr	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
plasma	NN	plasma	plasma	plasma	N	I-AdverseReaction
zinc	NN	zinc	zinc	zinc	Y	I-AdverseReaction
concentrations	NNS	concentrations	concentration	concentr	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
on	IN	on	on	on	N	O
Ferriprox	NNP	ferriprox	ferriprox	ferriprox	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
plasma	NN	plasma	plasma	plasma	N	O
zinc	NN	zinc	zinc	zinc	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
supplement	NN	supplement	supplement	supplement	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
deficiency	NN	deficiency	deficiency	defici	N	O
.	.	.	.	.	N	O

